Company intelligence / Profile preview

MabVax Therapeutics

San Diego, California, United Statesmabvax.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

MabVax developed fully human monoclonal antibodies and vaccine-based therapies for the treatment of cancers expressing specific tumor-associated antigens. Its lead program was a fully human IgG1 mAb targeting sialyl Lewis A/CA19–9 for pancreatic and other cancers. Early clinical studies demonstrated safety, specificity to target antigen, and potential efficacy signals in Phase I trials. The company also advanced a PET imaging agent and a radioimmunotherapy into early clinical development.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)VaccinesRadioimmunotherapy
Industry: Biotech

Drug pipeline

8 assets

MVT-5873

7 more assets in the full pipeline.

Partnerships

Memorial Sloan Kettering Cancer CenterRockefeller UniversitySarah Cannon Research InstituteHonor HealthImaging Endpoints

Beyond the preview

Go deeper on MabVax Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MabVax Therapeutics.